GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and ...

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

GoodRx (GDRX) is joining in on the GLP-1 action with an announcement on Monday that it will begin selling both of Novo Nordisk's (NVO) GLP-1 drugs, Ozempic for diabetes and Wegovy for weight loss, at ...

Novo Nordisk makes the wildly popular GLP-1 drug semaglutide which it sells under the brand name Wegovy for weight-loss and ...

When the FDA took Novo Nordisk and Eli Lilly’s GLP-1 medications off of the drug shortage list, the move should have been a ...

The launch marked Danish drugmaker Novo Nordisk's debut on the continent, ramping up competition with rival Eli Lilly.

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

Tonmya – a new under-the-tongue formulation of well-established muscle relaxant cyclobenzaprine HCl – has been cleared to ...

The company said Friday that it received FDA approval for a new Wegovy indication as a treatment of a fatty liver disease known as metabolic dysfunction-associated steatohepatitis, or MASH, in adults ...

Dining under palm trees on a patio at Mar-a-Lago in December, President-elect Donald Trump reassured chief executives at ...

Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver ...